Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL)
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Non-alcoholic fatty liver disease (NAFLD) develops due to impaired hepatic lipid fluxes and is a risk factor for chronic liver disease and atherosclerosis. Lipidomic studies consistently reported characteristic hepatic/VLDL "lipid signatures" in NAFLD; whole plasma traits are more debated. Surprisingly, the HDL lipid composition by mass spectrometry has not been characterised across the NAFLD spectrum, despite HDL being a possible source of hepatic lipids delivered from peripheral tissues alongside free fatty acids (FFA). This study characterises the HDL lipidomic signature in NAFLD, and its correlation with metabolic and liver disease markers. METHODS: We used liquid chromatography-mass spectrometry to determine the whole serum and HDL lipidomic profile in 89 biopsy-proven NAFLD patients and 20 sex and age-matched controls. RESULTS: In the whole serum of NAFLD versus controls, we report a depletion in polyunsaturated (PUFA) phospholipids (PL) and FFA; with PUFA PL being also lower in HDL, and negatively correlated with BMI, insulin resistance, triglycerides, and hepatocyte ballooning. In the HDL of the NAFLD group we also describe higher saturated ceramides, which positively correlate with insulin resistance and transaminases. CONCLUSION: NAFLD features lower serum lipid species containing polyunsaturated fatty acids; the most affected lipid fractions are FFA and (HDL) phospholipids; our data suggest a possible defect in the transfer of PUFA from peripheral tissues to the liver in NAFLD. Mechanistic studies are required to explore the biological implications of our findings addressing if HDL composition can influence liver metabolism and damage, thus contributing to NAFLD pathophysiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 2×
“com perspective, NAFLD is a continuum of presentations ranging from “simple” steatosis (NAFL; intrahepatic fat deposition in more than 5% of hepatocytes) to steatohepatitis (NASH; steatosis in the presence of inflammation and ballooning), fibrosis, and cirrhosis, which can ultimately evolve to hepatocellular carcinoma…”
BackgroundA lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338 · cited 1×
“controls that we reported is aligned with previous whole serum studies [51e53] as well as with the acyl chain saturation profile of the whole hepatic lipidome [17,54,55].”
ResultBorkman, M., Storlien, L. H., Pan, D. A., Jenkins, A. B., Chisholm, D. J., & Campbell, L. V. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301283280404 · Cited by 835
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771 · cited 1×
“1a,b), likely reflecting the known activation of DNL programs previously described in NAFLD [11,14,26,27].”
BackgroundMantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00308-3 · Cited by 674 · cited 1×
“The latter represents the leading cause of death in these patients, and recent studies suggest that NALFD could be an independent risk factor for atherosclerosis and CVD outcomes [5].”
BackgroundLuukkonen, P. K., Zhou, Y., Sädevirta, S., Leivonen, M., Arola, J., Orešič, M., Hyötyläinen, T., & Yki-Järvinen, H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.002 · Cited by 461
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451
Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression
Sekiya, M., Yahagi, N., Matsuzaka, T., Najima, Y., Nakakuki, M., Nagai, R., Ishibashi, S., Osuga, J.-I., Yamada, N., & Shimano, H. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.028 · Cited by 415
Prieur, X., Mok, C. Y. L., Velagapudi, V. R., Núñez, V., Fuentes, L., Montaner, D., Ishikawa, K., Camacho, A., Barbarroja, N., O’Rahilly, S., et al. (2011) · Diabetes · doi:10.2337/db10-0705 · Cited by 381
Self-citationAzzu, V., Vacca, M., Virtue, S., Allison, M., & Vidal-Puig, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.054 · Cited by 369 · cited 10×
“EFA can negatively modulate the DNL machinery toward the negative modulation of the Liver X Receptor (LXR), of SREBP-1 and/or of the carbohydrate response element binding protein (ChREBP) [56e58].”
BackgroundInfluentialSelf-citationMusso, G., Cassader, M., Paschetta, E., & Gambino, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.031 · Cited by 332
Dentin, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25256 · Cited by 315
Chiappini, F., Coilly, A., Kadar, H., Gual, P., Tran, A., Desterke, C., Samuel, D., Duclos-Vallée, J.-C., Touboul, D., Bertrand-Michel, J., et al. (2017) · Scientific Reports · doi:10.1038/srep46658 · Cited by 246
Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis
TAVARES DE ALMEIDA, I., CORTEZ-PINTO, H., FIDALGO, G., RODRIGUES, D., & CAMILO, M. E. (2002) · Clinical Nutrition · doi:10.1054/clnu.2001.0529 · Cited by 243
Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function
Stadler, J. T., & Marsche, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238985 · Cited by 200
Kotronen, A., Velagapudi, V. R., Yetukuri, L., Westerbacka, J., Bergholm, R., Ekroos, K., Makkonen, J., Taskinen, M.-R., Orešič, M., & Yki-Järvinen, H. (2009) · Diabetologia · doi:10.1007/s00125-009-1282-2 · Cited by 198
Ooi, G. J., Meikle, P. J., Huynh, K., Earnest, A., Roberts, S. K., Kemp, W., Parker, B. L., Brown, W., Burton, P., & Watt, M. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.013 · Cited by 137 · cited 3×
“Some studies described increased hepatic Cer in NAFLD livers, and its association with lipotoxic damage [17,81].”
BackgroundResultSanders, F. W. B., Acharjee, A., Walker, C., Marney, L., Roberts, L. D., Imamura, F., Jenkins, B., Case, J., Ray, S., Virtue, S., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1439-8 · Cited by 114 · cited 1×
“1a,b), likely reflecting the known activation of DNL programs previously described in NAFLD [11,14,26,27].”
BackgroundSelf-citationCirculating phospholipid profiling identifies portal contribution to NASH signature in obesity
Anjani, K., Lhomme, M., Sokolovska, N., Poitou, C., Aron-Wisnewsky, J., Bouillot, J.-L., Lesnik, P., Bedossa, P., Kontush, A., Clement, K., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.002 · Cited by 106 · cited 1×
“Discordances have also been reported among major plasma lipidomic classes: for example, PL have been described higher (PC/SM [16]; PC/PE/PG [42]), and/or lower (PC/ LPC/SM [13]; LPC [43]) in NAFLD compared to controls.”
ResultDifferent Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load
Gambino, R., Bugianesi, E., Rosso, C., Mezzabotta, L., Pinach, S., Alemanno, N., Saba, F., & Cassader, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040479 · Cited by 101
Tiwari-Heckler, S., Gan-Schreier, H., Stremmel, W., Chamulitrat, W., & Pathil, A. (2018) · Nutrients · doi:10.3390/nu10050649 · Cited by 96
Azzu, V., Vacca, M., Kamzolas, I., Hall, Z., Leslie, J., Carobbio, S., Virtue, S., Davies, S. E., Lukasik, A., Dale, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101210 · Cited by 52 · cited 2×
“1a,b), likely reflecting the known activation of DNL programs previously described in NAFLD [11,14,26,27].”
BackgroundResultSelf-citation
Research works printed but not linked: 62
- Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 · DOI · Paper page
- Targher, 2020, NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications, Gut, 69, 1691, 10.1136/gutjnl-2020-320622 · DOI · Paper page
- Guerra, 2022, Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis, Eur J Clin Invest, 52, 10.1111/eci.13695 · DOI
- Morigny, 2021, Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics, Nat Rev Endocrinol, 17, 276, 10.1038/s41574-021-00471-8 · DOI · Paper page
- Mocciaro, 2022, Obesity-related insulin resistance: the central role of adipose tissue dysfunction, Handb Exp Pharmacol, 274, 145, 10.1007/164_2021_573 · DOI
- Mayo, 2018, Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts, Hepatol Commun, 2, 807, 10.1002/hep4.1188 · DOI · Paper page
- Yang, 2017, Serum monounsaturated triacylglycerol predicts steatohepatitis in patients with non-alcoholic fatty liver disease and chronic hepatitis B, Sci Rep, 7
- Zhou, 2016, Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites, Clin Gastroenterol Hepatol, 14, 1463, 10.1016/j.cgh.2016.05.046 · DOI
- Donnelly, 2005, Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J Clin Invest, 115, 1343, 10.1172/JCI23621 · DOI · Paper page
- Capel, 2020, Metabolomics reveals plausible interactive effects between dairy product consumption and metabolic syndrome in humans, Clin Nutr, 39, 1497, 10.1016/j.clnu.2019.06.013 · DOI
- Seyres, 2022, Transcriptional, epigenetic and metabolic signatures in cardiometabolic syndrome defined by extreme phenotypes, Clin Epigenetics, 14, 39, 10.1186/s13148-022-01257-z · DOI
- Mocciaro, 2022, Lipidomic approaches to study HDL metabolism in patients with central obesity diagnosed with metabolic syndrome, Int J Mol Sci, 23, 10.3390/ijms23126786 · DOI
- Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
- Bedossa, 2012, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 56, 1751, 10.1002/hep.25889 · DOI · Paper page
- Kotronen, 2009, Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors, Gastroenterology, 137, 865, 10.1053/j.gastro.2009.06.005 · DOI · Paper page
- Meikle, 2017, Sphingolipids and phospholipids in insulin resistance and related metabolic disorders, Nat Rev Endocrinol, 13, 79, 10.1038/nrendo.2016.169 · DOI · Paper page
- Beyene, 2020, Correction: high-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: evidence from two large population cohort studies, PLoS Biol, 18, 10.1371/journal.pbio.3001049 · DOI
- Bui, 2012, Analysis of sphingolipids in extracted human plasma using liquid chromatography electrospray ionization tandem mass spectrometry, Anal Biochem, 423, 187, 10.1016/j.ab.2012.01.027 · DOI
- Hammad, 2010, Blood sphingolipidomics in healthy humans: impact of sample collection methodology, J Lipid Res, 51, 3074, 10.1194/jlr.D008532 · DOI · Paper page
- Mielke, 2015, Demographic and clinical variables affecting mid- to late-life trajectories of plasma ceramide and dihydroceramide species, Aging Cell, 14, 1014, 10.1111/acel.12369 · DOI
- Vvedenskaya, 2021, Nonalcoholic fatty liver disease stratification by liver lipidomics, J Lipid Res, 62, 10.1016/j.jlr.2021.100104 · DOI
- Ferrara, 2021, Lysophospholipid acylation modulates plasma membrane lipid organization and insulin sensitivity in skeletal muscle, J Clin Invest, 131, 10.1172/JCI135963 · DOI
- Pietilainen, 2011, Association of lipidome remodeling in the adipocyte membrane with acquired obesity in humans, PLoS Biol, 9, 10.1371/journal.pbio.1000623 · DOI · Paper page
- Singaraja, 2006, Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo, Circulation, 114, 1301, 10.1161/CIRCULATIONAHA.106.621433 · DOI · Paper page
- Sano, 2007, Sphingomyelin-dependence of cholesterol efflux mediated by ABCG1, J Lipid Res, 48, 2377, 10.1194/jlr.M700139-JLR200 · DOI
- Camont, 2013, Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities, Arterioscler Thromb Vasc Biol, 33, 2715, 10.1161/ATVBAHA.113.301468 · DOI · Paper page
- van der Veen, 2012, The membrane lipid phosphatidylcholine is an unexpected source of triacylglycerol in the liver, J Biol Chem, 287, 23418, 10.1074/jbc.M112.381723 · DOI · Paper page
- Kartsoli, 2020, Lipidomics in non-alcoholic fatty liver disease, World J Hepatol, 12, 436, 10.4254/wjh.v12.i8.436 · DOI
- Oresic, 2013, Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids, Diabetologia, 56, 2266, 10.1007/s00125-013-2981-2 · DOI · Paper page
- Ding, 2020, A review of lipidomics of cardiovascular disease highlights the importance of isolating lipoproteins, Metabolites, 10, 10.3390/metabo10040163 · DOI
- Kontush, 2013, Unraveling the complexities of the HDL lipidome, J Lipid Res, 54, 2950, 10.1194/jlr.R036095 · DOI · Paper page
- Boon, 2013, Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance, Diabetes, 62, 401, 10.2337/db12-0686 · DOI · Paper page
- Carlier, 2020, Dihydroceramides in triglyceride-enriched VLDL are associated with nonalcoholic fatty liver disease severity in type 2 diabetes, Cell Rep Med, 1
- Bevilacqua, 1987, Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects, Metabolism, 36, 502, 10.1016/0026-0495(87)90051-5 · DOI · Paper page
- Lomonaco, 2012, Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease, Hepatology, 55, 1389, 10.1002/hep.25539 · DOI · Paper page
- Feng, 2017, Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: a case - control study, Lipids Health Dis, 16, 165, 10.1186/s12944-017-0551-1 · DOI · Paper page
- Ducheix, 2013, Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor, J Hepatol, 58, 984, 10.1016/j.jhep.2013.01.006 · DOI
- Neschen, 2007, n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner, Diabetes, 56, 1034, 10.2337/db06-1206 · DOI · Paper page
- Scorletti, 2018, Omega-3 fatty acids and non-alcoholic fatty liver disease: evidence of efficacy and mechanism of action, Mol Aspects Med, 64, 135, 10.1016/j.mam.2018.03.001 · DOI · Paper page
- Hodson, 2008, Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake, Prog Lipid Res, 47, 348, 10.1016/j.plipres.2008.03.003 · DOI · Paper page
- Leaf, 1995, Incorporation of dietary n-3 fatty acids into the fatty acids of human adipose tissue and plasma lipid classes, Am J Clin Nutr, 62, 68, 10.1093/ajcn/62.1.68 · DOI
- Jacobsen, 1983, Acyl pattern of adipose tissue triglycerides, plasma free fatty acids, and diet of a group of men participating in a primary coronary prevention program (the Oslo Study), Am J Clin Nutr, 38, 906, 10.1093/ajcn/38.6.906 · DOI
- Parry, 2021, Oxidation of dietary linoleate occurs to a greater extent than dietary palmitate in vivo in humans, Clin Nutr, 40, 1108, 10.1016/j.clnu.2020.07.013 · DOI
- Burke, 2009, Phospholipase A2 biochemistry, Cardiovasc Drugs Ther, 23, 49, 10.1007/s10557-008-6132-9 · DOI · Paper page
- Schwendeman, 2015, The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties, J Lipid Res, 56, 1727, 10.1194/jlr.M060285 · DOI · Paper page
- Hong, 2022, Effect of lipid composition on the atheroprotective properties of HDL-mimicking micelles, Pharmaceutics, 14, 10.3390/pharmaceutics14081570 · DOI
- McCullough, 2019, HDL flux is higher in patients with nonalcoholic fatty liver disease, Am J Physiol Endocrinol Metab, 317, E852, 10.1152/ajpendo.00193.2019 · DOI
- Di Costanzo, 2020, HDL-mediated cholesterol efflux and plasma loading capacities are altered in subjects with metabolically- but not genetically driven non-alcoholic fatty liver disease (NAFLD), Biomedicines, 8, 10.3390/biomedicines8120625 · DOI
- Fadaei, 2018, Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis, Sci Rep, 8, 10.1038/s41598-018-29639-5 · DOI · Paper page
- Zannis, 2015, HDL biogenesis, remodeling, and catabolism, Handb Exp Pharmacol, 224, 53, 10.1007/978-3-319-09665-0_2 · DOI · Paper page
- Robichaud, 2009, Hepatic uptake and metabolism of phosphatidylcholine associated with high density lipoproteins, Biochim Biophys Acta, 1790, 538, 10.1016/j.bbagen.2009.02.010 · DOI
- Borggreve, 2003, Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins, Eur J Clin Invest, 33, 1051, 10.1111/j.1365-2362.2003.01263.x · DOI · Paper page
- D'Amore, 2018, Identification of miR-9-5p as direct regulator of ABCA1 and HDL-driven reverse cholesterol transport in circulating CD14+ cells of patients with metabolic syndrome, Cardiovasc Res, 114, 1154, 10.1093/cvr/cvy077 · DOI
- Prada, 2021, Association of the odd-chain fatty acid content in lipid groups with type 2 diabetes risk: a targeted analysis of lipidomics data in the EPIC-Potsdam cohort, Clin Nutr, 40, 4988, 10.1016/j.clnu.2021.06.006 · DOI
- Imamura, 2017, A combination of plasma phospholipid fatty acids and its association with incidence of type 2 diabetes: the EPIC-InterAct case-cohort study, PLoS Med, 14, 10.1371/journal.pmed.1002409 · DOI
- Abdullah, 2015, Recommended dairy product intake modulates circulating fatty acid profile in healthy adults: a multi-centre cross-over study, Br J Nutr, 113, 435, 10.1017/S0007114514003894 · DOI
- Weitkunat, 2017, Odd-chain fatty acids as a biomarker for dietary fiber intake: a novel pathway for endogenous production from propionate, Am J Clin Nutr, 105, 1544, 10.3945/ajcn.117.152702 · DOI · Paper page
- Jenkins, 2017, Odd chain fatty acids; new insights of the relationship between the gut microbiota, dietary intake, biosynthesis and glucose intolerance, Sci Rep, 7, 10.1038/srep44845 · DOI
- Wallace, 2018, Enzyme promiscuity drives branched-chain fatty acid synthesis in adipose tissues, Nat Chem Biol, 14, 1021, 10.1038/s41589-018-0132-2 · DOI · Paper page
- Iqbal, 2015, Microsomal triglyceride transfer protein transfers and determines plasma concentrations of ceramide and sphingomyelin but not glycosylceramide, J Biol Chem, 290, 25863, 10.1074/jbc.M115.659110 · DOI
- Chaurasia, 2021, Ceramides in metabolism: key lipotoxic players, Annu Rev Physiol, 83, 303, 10.1146/annurev-physiol-031620-093815 · DOI · Paper page
- Patanapirunhakit, 2021, Sphingolipids in HDL - potential markers for adaptation to pregnancy?, Biochim Biophys Acta Mol Cell Biol Lipids, 1866
Cited by
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
“63,64 However, in individuals with the patatin-like phospholipase domain-containing protein 3 ( PNPLA3 )-148M variant, less VLDL is produced than in those homozygous for PNPLA3 -148I, 65 while those with the TM6SF2 (transmembrane 6 superfamily member 2) E167K genetic variant have a defect in VLDL…”
Self-citationKetogenesis supports hepatic polyunsaturated fatty acid homeostasis via fatty acid elongation
Queathem, E. D., Moazzami, Z., Stagg, D. B., Nelson, A. B., Fulghum, K., Hayir, A., Seay, A., Gillingham, J. R., d’Avignon, D. A., Han, X., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads0535 · Cited by 30
Szustak, M., Pichlak, M., Korkus, E., Kamińska, D., Koziołkiewicz, M., Dąbrowski, G., Czaplicki, S., Konopka, I., & Gendaszewska-Darmach, E. (2026) · Scientific Reports · doi:10.1038/s41598-026-37006-y · Cited by 5
Metadata
- Authors
- Mocciaro, G., Allison, M., Jenkins, B., Azzu, V., Huang-Doran, I., Herrera-Marcos, L. V., Hall, Z., Murgia, A., Susan, D., Frontini, M., Vidal-Puig, A., Koulman, A., Griffin, J. L., & Vacca, M.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 73
- Pages
- 101728
- ISSN
- 2212-8778 (ISSN-L)
- OpenAlex
- W4366418525
- Cited by
- 56
- References
- 22
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- UKRI Medical Research Council (MC PC 13030, MR/W019132/1, MC UP A90 1006)
- Governo Italiano Ministero dell'Istruzione dell'Università e della Ricerca
- NIHR Cambridge Biomedical Research Centre (IS-BRC-1215-20014)
- Mason Medical Research Trust
- University of Bari Aldo Moro
- Foundation for Liver Research
- National Institute for Health and Care Research
- Evelyn Trust
- BHF
- Associazione Italiana per la Ricerca sul Cancro (27521, IG2022)
- British Heart Foundation (FS/18/53/33863)
- University of Cambridge
- Academy of Medical Sciences
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.